Research Paper Volume 13, Issue 17 pp 21497—21512

Figure 1. ALKBH5 was downregulated in ESCC tissue specimens, and its downregulation was associated with advanced TNM and clinical stages of ESCC. (A) Representative immunohistochemistry images showing ALKBH5 protein expression in adjacent non-tumor (NT) and ESCC tissue specimens. (a) High expression of ALKBH5 in adjacent non-tumor (NT) specimens. (b) High expression of ALKBH5 in ESCC specimens. (c) Low expression of ALKBH5 in ESCC specimens. The brown staining indicates ALKBH5 immunoreactivity. (B) IHC assay revealed lower ALKBH5 expression in ESCC tissue specimens than in the adjacent healthy tissues (P < 0.01, ᵡ² test). (C) Western blots showing ALKBH5 protein expression in ESCC specimens and paired adjacent NT biopsies. (D) Western blotting revealed lower ALKBH5 expression in ESCC tissue specimens than in the adjacent healthy tissues. (E) Representative images of ALKBH5 expression in ESCC biopsies with different TNM and clinical stages. High expression of ALKBH5 was observed in clinical stages I (a), T2 (c), N0 (e), M0 (g) and histological grade II (i) of ESCC biopsies, whereas low expression of ALKBH5 was detected in clinical stages III (b), T4 (d), N1 (f), and M1 (h), and histological grade III (j). (F) Numbers and percentages of disease cases with high or low expression of ALKBH5 according to different clinicopathological features.